DS
Therapeutic Areas
Renalytix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KidneyIntelX | Risk prediction for progressive kidney function decline in patients with Type 2 diabetes and early-stage chronic kidney disease (CKD) | Approved |
| KidneyIntelX.dkd | Diabetic kidney disease (DKD) risk assessment | Approved |
Leadership Team at Renalytix
JM
James McCullough
Chief Executive Officer
OJ
O. James Sterling
Chief Financial Officer
MJ
Michael J. Donovan
Chief Medical Officer
DF
Dr. Fergus Fleming
Chief Technology Officer
DB
Dr. Barbara Murphy
Chair of the Scientific Advisory Board
DE
Dr. Eli A. Friedman
Medical Advisor
DG
Dr. Girish N. Nadkarni
Scientific Co-Founder and Advisor
SC
Sir Christopher Evans
Non-Executive Director
DJ
Daniel J. Levangie
Non-Executive Director
TR
Timothy R. Scannell
Non-Executive Director